Stay updated with breaking news from Circulating Tumor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Blood-based test for comprehensive genomic profiling of solid cancers meets requirements under stricter EU In Vitro Diagnostic Regulation IVDR certification from TÜV SÜD enables broader adoption
/PRNewswire/ -- DelveInsight's Liquid Biopsy in Cancer Diagnostics Market Insights report provides the current and forecast market analysis, individual leading...
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium ...
Decisions regarding the intensification or de-escalation of treatment, particularly with immunotherapy and TKIs, for patients with renal cell carcinoma could be aided by circulating tumor DNA.
Postoperative circulating tumor DNA (ctDNA)–based minimal residual disease status demonstrated prognostic value for patients with stage 1 to 4 resected colorectal cancer, showing that those with positive ctDNA after surgery have significantly lower disease-free survival outcomes at 24 months vs those who were ctDNA negative.